MRNA vs BNTX โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
BNTX Captures Institutional Edge (2โ2 Pillars ยท 7โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to BioNTech SE American Depositary Share (BNTX) driven by superior Valuation, Growth & Margin while MRNA counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, MRNA trades at 23.0x Forward P/E with -80.8% operating margin (+29.2% YoY revenue) versus BNTX at 7.0x Forward P/E and -55.5% operating margin (-15.1% YoY). In options structure, MRNA sits in CONSOLIDATION (52nd %ile IV; Dealer Gamma Walls on Pro) against BNTX sits in UNCLASSIFIED (76th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | MRNA | BNTX | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $80.7B | $20.2B | Larger Scale | MRNA |
| Trailing P/E Ratio Valuation | 23.0x | 7.0x | Lower Multiple | BNTX |
| Forward P/E Ratio Valuation | 23.0x | 7.0x | Lower Multiple | BNTX |
| Revenue Growth (YoY) Growth | +29.2% | -15.1% | Higher Growth | MRNA |
| Operating Margin (TTM) Profitability | -80.8% | -55.5% | Higher Margin | BNTX |
| Net Profit Margin Profitability | -110.5% | -60.9% | Higher Margin | BNTX |
| Return on Equity (ROE) Capital Efficiency | -34.5% | -8.1% | Higher ROE | BNTX |
| 52-Week Range Position Momentum | 67% ($22โ$281) | 3% ($80โ$124) | Stronger Trend | MRNA |
| Beta / 30D Volatility Risk Regime | 2.23ฮฒ ยท 78% Vol | 0.77ฮฒ ยท 30% Vol | Lower Realized Risk | BNTX |
| Unified Institutional Score Composite Signal | 40.3 / 100 (SELL) | 41.8 / 100 (SELL) | Higher Composite | BNTX |